Answer
Alirocumab binds PCSK9 and prevents it from binding LDL receptors, reducing receptor degradation and increasing the number of liver LDL receptors available to clear LDL from the blood, thereby lowering LDL cholesterol.
Sources for this answer
- Praluent 75 mg solution for injection in pre filled penSANOFI · emc · SmPC §5.1 Pharmacodynamic properties · Version 7Document updated
Sources checked